Why do some patients respond to certain cancer treatments, while others simply do not?
Researchers investigating immunotherapy and T-cell resistant cancers are using genomic tools in new ways. A team of scientists have harnessed the specificity of CRISPR, a gene-editing technology, to ‘knock out’ every one of the 19,000 protein-encoding genes of human melanoma cells. These genetically modified melanoma cells were then tested for their response to T-cell Therapy.
Researchers found over 100 genes whose presence in cancer cells potentially dictates the success of T-cells in destroying cancer cells. Many of these identified genes have been further associated with tumor cytolytic activity potentially bringing clinicians another few steps closer to effective cancer treatment.
Image: Neu Paddy / CC0 Creative Commons
This story is taken from the 11 August 2017 edition of The Warren Centre’s Prototype newsletter. Sign up for the Prototype here.